Details

Autor(en) / Beteiligte

• Higgins, Kristin A.
• Simone, Charles B.
• Amini, Arya
• Chetty, Indrin J.
• Donington, Jessica
• Edelman, Martin J.
• Chun, Stephen G.
• Kestin, Larry L.
• Movsas, Benjamin
• Rodrigues, George B.
• Rosenzweig, Kenneth E.
• Slotman, Ben J.
• Rybkin, Igor I.
• Wolf, Andrea
• Chang, Joe Y.

Titel

American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC

Ist Teil von

• Journal of thoracic oncology, 2021-01, Vol.16 (1), p.54-65

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The standard-of-care therapy for extensive-stage SCLC has recently changed with the results of two large randomized trials revealing improved survival with the addition of immunotherapy to first-line platinum or etoposide chemotherapy. This has led to a lack of clarity around the role of consolidative thoracic radiation and prophylactic cranial irradiation in the setting of chemoimmunotherapy. The American Radium Society Appropriate Use Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with the application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for extensive-stage SCLC. Current evidence supports either prophylactic cranial irradiation or surveillance with magnetic resonance imaging every 3 months for patients without evidence of brain metastases. Patients with brain metastases should receive whole-brain radiation with a recommended dose of 30 Gy in 10 fractions. Consolidative thoracic radiation can be considered in selected cases with the recommended dose ranging from 30 to 54 Gy; this recommendation was driven by expert opinion owing to the limited strength of evidence, as clinical trials addressing this question remain ongoing. Radiation therapy remains an integral component in the treatment paradigm for ES-SCLC.